AWAK PD Attracts Funding
Singapore-based Awak PD won FDA breakthrough device designation after completing its first-in-human study in October 2018, with no serious adverse events, and has now raised $40M in a financing round to support late-stage clinical studies and commercialization of its portable, wearable, sorbent-based PD device.
Read the full article » | Posted 01-09-2020
Related Articles
- Byonyks’ X1 APD Cycler Received FDA 510(k) Approval Last Summer Posted 02-17-2026
- FDA granted 510(k) approval to Outset for Next generation Tablo with Cybersecurity Posted 02-17-2026
- Drs. Monica Farcus and Jeffrey Perl Win the Mitchell Award for Health System Innovation Posted 01-16-2026
- Nephrodite Wins FDA Breakthrough Device Designation for “Holly” Posted 01-16-2026